CN119587493A - 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物 - Google Patents

治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物 Download PDF

Info

Publication number
CN119587493A
CN119587493A CN202411683584.7A CN202411683584A CN119587493A CN 119587493 A CN119587493 A CN 119587493A CN 202411683584 A CN202411683584 A CN 202411683584A CN 119587493 A CN119587493 A CN 119587493A
Authority
CN
China
Prior art keywords
subject
smoking
weeks
administration
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411683584.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·雅克布斯
D·F·蔡恩
A·科莱克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Archway Life Sciences
Original Assignee
Archway Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archway Life Sciences filed Critical Archway Life Sciences
Publication of CN119587493A publication Critical patent/CN119587493A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202411683584.7A 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物 Pending CN119587493A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962899637P 2019-09-12 2019-09-12
US62/899,637 2019-09-12
US202062988890P 2020-03-12 2020-03-12
US62/988,890 2020-03-12
PCT/US2020/046308 WO2021050203A1 (en) 2019-09-12 2020-08-14 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
CN202080064060.3A CN114727647A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080064060.3A Division CN114727647A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Publications (1)

Publication Number Publication Date
CN119587493A true CN119587493A (zh) 2025-03-11

Family

ID=74866435

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202411683584.7A Pending CN119587493A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN202411684617.XA Pending CN119564619A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN202080064060.3A Pending CN114727647A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN202410180790.XA Pending CN118286217A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202411684617.XA Pending CN119564619A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN202080064060.3A Pending CN114727647A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN202410180790.XA Pending CN118286217A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Country Status (11)

Country Link
US (3) US11083715B2 (https=)
EP (1) EP4027815B1 (https=)
JP (2) JP7742832B2 (https=)
KR (1) KR20220074895A (https=)
CN (4) CN119587493A (https=)
AU (1) AU2020346695A1 (https=)
BR (1) BR112022004519A2 (https=)
CA (1) CA3153405A1 (https=)
MX (1) MX2022002882A (https=)
WO (1) WO2021050203A1 (https=)
ZA (1) ZA202204075B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
EP4399517A4 (en) * 2021-09-08 2025-10-15 Achieve Life Sciences Inc ANALYTICAL METHODS FOR EVALUATING THE PURITY OF CYTISINE
JP2024095092A (ja) * 2022-12-28 2024-07-10 株式会社日立製作所 生成装置、生成方法、および生成プログラム
WO2024226736A2 (en) * 2023-04-26 2024-10-31 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125699B (en) 1982-02-22 1986-02-12 Bruss Ni Sanitarno Gigieniches Medicinal preparation having antinicotine effect and method for obtention thereof
WO1998018798A1 (en) * 1996-10-30 1998-05-07 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
CN104906669A (zh) * 2007-03-30 2015-09-16 菲利普莫里斯生产公司 用于输送药剂的装置和方法
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
WO2014205449A2 (en) * 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
JP6324964B2 (ja) 2013-08-23 2018-05-16 久光製薬株式会社 貼付剤
PL409829A1 (pl) * 2014-10-18 2016-04-25 Łukasz Zalewski Płyn z cytyzyną do elektronicznych papierosów
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
EP3658561A1 (en) * 2017-07-24 2020-06-03 Achieve Pharma UK Limited Cytisine salts
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Also Published As

Publication number Publication date
EP4027815A4 (en) 2023-06-07
AU2020346695A1 (en) 2022-04-28
WO2021050203A1 (en) 2021-03-18
KR20220074895A (ko) 2022-06-03
JP2022548876A (ja) 2022-11-22
EP4027815A1 (en) 2022-07-20
CN114727647A (zh) 2022-07-08
US20210330652A1 (en) 2021-10-28
CN118286217A (zh) 2024-07-05
US20210077475A1 (en) 2021-03-18
EP4027815B1 (en) 2026-04-15
CN119564619A (zh) 2025-03-07
US20210077473A1 (en) 2021-03-18
MX2022002882A (es) 2022-05-10
US11083715B2 (en) 2021-08-10
JP7742832B2 (ja) 2025-09-22
CA3153405A1 (en) 2021-03-18
ZA202204075B (en) 2023-11-29
JP2025081331A (ja) 2025-05-27
US11083716B2 (en) 2021-08-10
BR112022004519A2 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
Henningfield et al. Pharmacotherapy for Nicotine Dependence 1
CN119587493A (zh) 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
Newmeyer et al. Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration
Upadhyaya et al. Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study
Bailey et al. A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers
WO2011020061A2 (en) Compositions and methods of for treating bipolar disorder
US20120225949A1 (en) Compositions and methods for treating bipolar disorder
Wagen et al. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease
Cornuz Smoking cessation interventions in clinical practice
Ordak et al. Pharmacotherapy of patients taking new psychoactive substances: a systematic review and analysis of case reports
Miller et al. Cigarette mentholation increases smokers' exhaled carbon monoxide levels.
CN121532188A (zh) 包含金雀花碱的组合物用于治疗和/或预防有此需要的受试者的成瘾
Harlivasari et al. The role of twice-daily N-acetylcysteine (NAC) 2400 mg in smoking cessation: a randomized, placebo-controlled trial in Indonesia
Suchanek Hudmon et al. Current approaches to pharmacotherapy for smoking cessation
Farnam Zyban: a new aid to smoking cessation treatment--will it work for psychiatric patients?
US20200093764A1 (en) Treatment of asthma with cysteamine
van Lemmen et al. Reversal of fentanyl-induced apnea: a randomized comparison between intramuscular (Zimhi) and intranasal naloxone (Narcan)
Glover Successfully treating nicotine dependence
Truong Stimulants and Co-occurring Substance Use
Clements Medications for Smoking Cessation
Andrews et al. Nicotine addiction: Current treatment options
JP2024514546A (ja) 亜酸化窒素により治療抵抗性うつ病性障害を治療するための組成物及び方法
Sullivan et al. State of the art reviews: smoking cessation: a review of treatment considerations
Adhikari et al. A Discussion about Modalities of Smoking Cessation in Perioperative Phase for Addicts: A Review Article
Andreaci et al. " Tobacco free with FDNY"-The New York City Fire Department World Trade Center tobacco cessation study

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination